[{"address1": "One Kendall Square", "address2": "Building 1400 West 3rd Floor", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "(617) 651-8867", "website": "https://www.camp4tx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 58, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joshua  Mandel-Brehm", "age": 40, "title": "CEO, President & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 696281, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard A. Young Ph.D.", "age": 69, "title": "Founder & Independent Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 142500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Gold", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 628834, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Bumcrot Ph.D.", "age": 61, "title": "Chief Scientific Officer & Senior Vice President of Research", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 501933, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Leonard I. Zon M.D.", "title": "Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Caleb  Moore", "title": "Chief Business Operations Officer & SVP of Portfolio Strategy & Business Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Gates", "title": "Senior VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Satya  Kuchimanchi Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel  Tardiff Ph.D.", "title": "VP & Head of Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yuri  Maricich M.B.A., M.D.", "age": 42, "title": "Chief Medical Officer", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.49, "open": 6.46, "dayLow": 5.4052, "dayHigh": 6.7, "regularMarketPreviousClose": 6.49, "regularMarketOpen": 6.46, "regularMarketDayLow": 5.4052, "regularMarketDayHigh": 6.7, "forwardPE": -1.9003356, "volume": 88504, "regularMarketVolume": 88504, "averageVolume": 127566, "averageVolume10days": 202310, "averageDailyVolume10Day": 202310, "bid": 5.24, "ask": 5.78, "bidSize": 100, "askSize": 100, "marketCap": 109474768, "fiftyTwoWeekLow": 4.06, "fiftyTwoWeekHigh": 12.3, "priceToSalesTrailing12Months": 312.78506, "fiftyDayAverage": 8.1456, "twoHundredDayAverage": 8.322593, "currency": "USD", "enterpriseValue": 162895264, "floatShares": 82035, "sharesOutstanding": 20161100, "sharesShort": 256614, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0194, "heldPercentInsiders": 0.36591, "heldPercentInstitutions": 0.42041, "shortRatio": 2.72, "shortPercentOfFloat": 0.0251, "impliedSharesOutstanding": 20161100, "bookValue": -268.567, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -49713000, "trailingEps": -2.64, "forwardEps": -3.01, "enterpriseToRevenue": 465.415, "enterpriseToEbitda": -3.283, "52WeekChange": -0.49347013, "SandP52WeekChange": 0.25891924, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CAMP", "underlyingSymbol": "CAMP", "shortName": "CAMP4 THERAPEUTICS CORPORATION", "firstTradeDateEpochUtc": 1728653400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "b3c26f55-b1d5-368c-93b3-b92b8939d995", "messageBoardId": "finmb_569025678", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.43, "targetHighPrice": 22.63, "targetLowPrice": 17.0, "targetMeanPrice": 19.9075, "targetMedianPrice": 20.0, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 12607000, "totalCashPerShare": 25.683, "ebitda": -49625000, "totalDebt": 10518000, "quickRatio": 1.664, "currentRatio": 1.899, "totalRevenue": 350000, "debtToEquity": 69.966, "revenuePerShare": 0.786, "operatingCashflow": -42918000, "operatingMargins": -146.7143, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]